|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-18.41/--
|
企业价值
33.35M
|
资产负债 |
每股账面净值
9.42
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
3.91
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 15:53 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS). |